NFKB1 and hepatocellular carcinoma: miR-26b significantly suppressed the NF-κB signaling and dramatically enhanced chemo-sensitivity of HCC to doxorubicin by targeting TAK1 and TAB3, two positive regulators of NF-κB pathway (432).